Agios Pharmaceuticals Inc (AGIO)

42.28
NASDAQ : Health Care
Prev Close 42.03
Day Low/High 40.90 / 42.45
52 Wk Low/High 33.50 / 67.74
Avg Volume 880.90K
Exchange NASDAQ
Shares Outstanding 42.01M
Market Cap 1.77B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.

Agios Provides Update On PKR Program

Agios Provides Update On PKR Program

Flagship Ventures Evolves Name To Flagship Pioneering

Flagship Ventures Evolves Name To Flagship Pioneering

Announces Innovative $285 Million Follow-on Capital Pool for Special Opportunities

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Agios Pharmaceuticals, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Agios Pharmaceuticals, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc.

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

Celgene And Agios Announce Collaborations With Abbott For Diagnostic Identification Of IDH Mutations In AML

Celgene And Agios Announce Collaborations With Abbott For Diagnostic Identification Of IDH Mutations In AML

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop...

Agios Shares Spike on Planned Drug Application

Agios Shares Spike on Planned Drug Application

The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.

Short Interest Increases 10.4% For AGIO

Short Interest Increases 10.4% For AGIO

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 680,325 share increase in total short interest for Agios Pharmaceuticals Inc , to 7,219,945, an increase of 10.40% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Agios Pharmaceuticals (AGIO) Highlighted As Weak On High Volume

Agios Pharmaceuticals (AGIO) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate